进展性脑梗死患者超敏C反应蛋白和脂蛋白a测定的临床研究

Clinical Study on High-sensitivity C-reactive Protein and Lipoprotein（a） tests in Patients of Progressive Cerebral Infarction

目的 探讨进展性脑梗死患者血清超敏C反应蛋白（hs-CRP）和脂蛋白a[Lp（a）]测定的临床价值.方法 检测31例进展性脑梗死患者（进展组）和35例非进展性脑梗死患者（非进展组）血请hs-CRP和Lp（a）水平,并与40名健康体检者（对照组）作对照.结果 进展组hs-CRP水平（11.33±2.76 mg/L）显著高于非进展组（6.35±2.15 mg/L）和健康对照组（1.28±0.92 mg/L）（P＜0.01）;进展组Lp（a）水平（485.63±186.80 mg/L）显著高于非进展组（311.75±28.51 mg/L）和健康对照组（106.87±63.41 mg/L）（P＜0.01）.结论 血清hs-CRP和Lp（a）联合检测对进展性脑梗死的诊断、病情严重程度、预后具有重要参考价值.

Objective To study the clinical value of testing serum high-sensitivity C-reactive protein （hs-CRP） and lipoprotein（a）[Lp（a）] in patients of progressive cerebral infarction. Methods The author tested serum hs-CRP and Lp （a） levels in 31 cases＇of progressive cerebral infarction patients（progression team） and 35 cases of non-progressive cerebral infarction patients （non-progression team） ,against the medial check-up results of a group of 40 healthy persons （control team）. Results Hs-CRP levels of the progression team （11.33±2.76 mg/L） were significantly higher than those of the non-progression team（6.35±2.15 rag/L） and the control team（1.28±0. 92 rag/L）（P〈0.01）;Lp（a） levels of the progression team （485.63± 186.80 rag/L） were significantly higher than those of the non-progression team （311.75/=28.51 mg/L）（P 〈0. 01） and the control team（10G 87±63.41 mg/L）（P〈0. 01）. Conclusion Combined testing of hs-CRP and Lp（a） is of high value to the diagnosis and prognosis of progressive cerebral infarction patients.